獸用皮膚病藥物市場規模、佔有率和成長分析：按藥物類別、給藥途徑、動物種類、適應症、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球獸用皮膚病藥物市場價值為 181 億美元，預計到 2033 年將從 2025 年的 198.4 億美元成長至 413 億美元，預測期（2026-2033 年）的複合年成長率為 9.6%。

全球獸醫皮膚病市場蓬勃發展，這主要得益於伴侶動物數量的成長以及飼主對寵物健康日益成長的期望，進而推動了對專業治療方法的需求。皮膚問題是寵物就診的常見原因，因此該市場涵蓋了多種皮膚疾病，包括過敏性皮膚炎和慢性膿皮病。傳統治療方法已從常用抗生素發展到奧克拉替尼和單株抗體等先進治療方法，顯著影響了獸醫實踐。隨著寵物飼主越來越將寵物視為家庭成員，他們也更願意投資先進的醫療手段，這吸引了製藥公司的注意。先進的診斷工具能夠更準確地識別疾病，從而促進標靶治療的應用，並減少對皮質類固醇的依賴。同時，奧克拉替尼等產品的成功表明，在全球新興市場，此類產品具有更高的定價潛力，並蘊藏投資機會。

全球獸用皮膚病藥物市場的成長要素

寵物飼主數量的不斷成長，以及人們將伴侶動物視為家庭成員的文化轉變，顯著提升了對高級獸醫護理的需求，尤其是在皮膚病學領域。寵物飼主越來越傾向於尋求專業的診斷和慢性皮膚病的持續治療，這促使獸醫更頻繁地開立專門的局部和全身治療藥物。這種日益成長的寵物健康投資意願和改善寵物生活品質的意願，正在推動市場成長，具體表現在促進創新產品的研發、拓展分銷管道以及推廣針對常見寵物皮膚病的新治療方法。

全球獸用皮膚病藥物市場限制因素

全球獸醫皮膚病市場面臨許多限制因素，包括創新皮膚病藥物和專利配方的高昂價格，令許多寵物飼主難以負擔。這種情況往往導致注重成本的獸醫診所在開立這些特殊治療方案時猶豫不決，從而限制了市場滲透率。研發和生產過程的高成本導致保險報銷不足，這可能使獸醫不願意推薦長期治療方案。當寵物飼主認為治療費用超過預期收益時，他們往往會選擇價格較低廉的症狀治療，這阻礙了先進治療方法的推廣應用，並縮小了整體市場基本客群。

全球獸用皮膚病藥物市場趨勢

全球獸醫皮膚病市場正經歷著一個顯著的趨勢，而這一趨勢的驅動力正是伴侶動物「人性化」的日益增強。寵物飼主越來越追求能夠體現自身健康標準的先進皮膚病治療方案。隨著期望值的提高，市場對專為寵物設計的高品質外用和內服藥物的需求也隨之激增。為了因應這一轉變，獸醫和產品研發人員正將安全性、生活方式融合以及更佳的美容效果放在首位，並將生活品質（QOL）因素納入治療方案。這一趨勢正在加速服務範圍的拓展，並促進獸醫診所與專業製造商之間的合作，從而創造出差異化的臨床服務和產品線，以滿足消費者對全面寵物健康和護膚護理的需求。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球獸用皮膚病藥物市場規模：依藥物類別分類

• 抗生素
  • 局部抗生素
  • 全身性抗生素
  • 其他
• 抗真菌藥物
• 抗發炎藥
• 驅蟲
• 免疫調節劑
• 抗組織胺藥
• 其他

全球獸用皮膚病藥物市場規模：依給藥途徑分類

• 口服
• 外用
• 注射藥物

全球獸用皮膚病藥物市場規模：依動物類型分類

• 伴侶動物
  • 狗
  • 貓
  • 其他
• 家畜
  • 牛
  • 豬
  • 家禽
  • 其他

全球獸用皮膚病藥物市場規模：依適應症分類。

• 過敏性皮膚炎
• 異位性皮膚炎
• 細菌性皮膚感染疾病
• 黴菌性皮膚感染疾病
• 寄生蟲性皮膚病
• 其他

全球獸用皮膚病藥物市場規模：依分銷管道分類

• 獸醫醫院和診所
• 零售藥房
• 網路藥房
• 其他

全球獸用皮膚病藥物市場規模：依最終用戶分類。

• 動物醫院
• 動物診所
• 動物收容所
• 畜牧場
• 其他

全球獸用皮膚病藥物市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Zoetis
• Elanco Animal Health
• Merck Animal Health
• Boehringer Ingelheim Animal Health
• Virbac
• Dechra Pharmaceuticals
• Ceva Sante Animale
• Vetoquinol
• Kindred Biosciences
• Bimeda
• Heska Corporation
• Phibro Animal Health
• Norbrook Laboratories
• Indian Immunologicals
• Neogen Corporation
• PetIQ
• Covetrus
• Chanelle Pharma
• Bioiberica
• Aurora Pharmaceutical

結論與建議

Global Veterinary Dermatology Drugs Market size was valued at USD 18.1 Billion in 2024 and is poised to grow from USD 19.84 Billion in 2025 to USD 41.3 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global veterinary dermatology drugs market is thriving due to increasing companion animal ownership and elevated pet health expectations among owners, driving the demand for specialized treatments. This market addresses various skin conditions, including allergic dermatitis and chronic pyoderma, as skin issues are common reasons pets visit vets. Traditional therapies have evolved from general antibiotics to advanced solutions like oclacitinib and monoclonal antibodies, significantly impacting veterinary practices. As pet owners treat their animals as family, their willingness to invest in advanced medical treatments has surged, enticing drug developers. Enhanced diagnostic tools enable precise identification of conditions, promoting the use of targeted therapies and reducing dependence on corticosteroids, while the success of products like oclacitinib demonstrates the opportunity for premium pricing and investment in new markets worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Veterinary Dermatology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Veterinary Dermatology Drugs Market Segments Analysis

Global veterinary dermatology drugs market is segmented by by drug class, by route of administration, by animal type, by indication, by distribution channel, by end user and region. Based on by drug class, the market is segmented into Antibacterial Drugs, Antifungal Drugs, Anti-inflammatory Drugs, Antiparasitic Drugs, Immunomodulators, Antihistamines and Others. Based on by route of administration, the market is segmented into Oral, Topical and Injectable. Based on by animal type, the market is segmented into Companion Animals and Livestock Animals. Based on by indication, the market is segmented into Allergic Dermatitis, Atopic Dermatitis, Bacterial Skin Infections, Fungal Skin Infections, Parasitic Skin Diseases and Others. Based on by distribution channel, the market is segmented into Veterinary Hospitals & Clinics, Retail Pharmacies, Online Pharmacies and Others. Based on by end user, the market is segmented into Veterinary Hospitals, Veterinary Clinics, Animal Shelters, Livestock Farms and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Veterinary Dermatology Drugs Market

The increasing number of pet owners, combined with a cultural shift towards treating companion animals as integral family members, has significantly boosted the demand for advanced veterinary care, particularly in dermatology. Pet owners are increasingly seeking professional diagnoses and ongoing management for chronic skin issues, prompting veterinarians to prescribe specialized topical and systemic treatments more frequently. A heightened willingness to invest in pet health and enhance quality of life drives market growth by fostering the development of innovative products, expanding distribution channels, and encouraging the adoption of new therapeutic options aimed at addressing common dermatological disorders in pets.

Restraints in the Global Veterinary Dermatology Drugs Market

The Global Veterinary Dermatology Drugs market faces significant constraints due to the premium pricing associated with innovative dermatological agents and proprietary formulations, which can restrict access for numerous pet owners. This situation often leads to cost-sensitive veterinary practices being hesitant to prescribe these specialized treatments, ultimately limiting market penetration. The high costs involved in the development and manufacturing processes may result in insufficient reimbursement options, causing veterinarians to be reluctant to endorse long-term treatment plans. When pet owners perceive that the costs outweigh the perceived benefits, they tend to opt for more affordable symptomatic treatments, thereby hampering the adoption of advanced therapies and reducing the overall customer base in the market.

Market Trends of the Global Veterinary Dermatology Drugs Market

The Global Veterinary Dermatology Drugs market is witnessing a notable trend driven by the humanization of companion animals, where pet owners are increasingly seeking advanced dermatological treatments that reflect their own health standards. As expectations rise, the demand for premium topical and systemic options tailored specifically for pets has surged. Responding to this shift, veterinarians and product developers are prioritizing safety, lifestyle compatibility, and improved aesthetic outcomes, thereby integrating quality-of-life considerations into treatment protocols. This trend promotes the expansion of service offerings and fosters collaboration between clinics and specialty manufacturers, resulting in differentiated clinical services and product lines that cater to consumers' desires for comprehensive pet wellness and skin care management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Veterinary Dermatology Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibacterial Drugs
  • Topical Antibiotics
  • Systemic Antibiotics
  • Others
• Antifungal Drugs
• Anti-inflammatory Drugs
• Antiparasitic Drugs
• Immunomodulators
• Antihistamines
• Others

Global Veterinary Dermatology Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Injectable

Global Veterinary Dermatology Drugs Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Companion Animals
  • Dogs
  • Cats
  • Others
• Livestock Animals
  • Cattle
  • Swine
  • Poultry
  • Others

Global Veterinary Dermatology Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Allergic Dermatitis
• Atopic Dermatitis
• Bacterial Skin Infections
• Fungal Skin Infections
• Parasitic Skin Diseases
• Others

Global Veterinary Dermatology Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

Global Veterinary Dermatology Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals
• Veterinary Clinics
• Animal Shelters
• Livestock Farms
• Others

Global Veterinary Dermatology Drugs Market Size & CAGR (2026-2033)

• North America (By Drug Class, By Route of Administration, By Animal Type, By Indication, By Distribution Channel, By End User)
  • US
  • Canada
• Europe (By Drug Class, By Route of Administration, By Animal Type, By Indication, By Distribution Channel, By End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug Class, By Route of Administration, By Animal Type, By Indication, By Distribution Channel, By End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Drug Class, By Route of Administration, By Animal Type, By Indication, By Distribution Channel, By End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Drug Class, By Route of Administration, By Animal Type, By Indication, By Distribution Channel, By End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kindred Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetIQ
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covetrus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chanelle Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioiberica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurora Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations